title: Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
abstract: Multiple myeloma has been associated with the development of thromboembolic events. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which potently inhibits fibrinolysis. The purpose of the present study was to assess the TAFI levels in patients with newly diagnosed multiple myeloma. Twenty-seven newly diagnosed multiple myeloma patients (16 women and 11 men) and 27 age-matched healthy individuals (14 women and 13 men) were included in the study. Serum TAFI levels were significantly increased in patients with multiple myeloma (46 ± 13. 3 vs. 36. 6 ± 9.7 μg/ml) compared with healthy individuals. Serum TAFI levels were negatively correlated with serum albumin (CC: -0.453, P < 0.05) and hemoglobin levels (CC: -0.392, P < 0.05) and positively correlated with the β-2 microglobulin levels (CC: 0.524, P < 0.05). In this study, we observed significantly elevated TAFI levels in patients with multiple myeloma and higher serum TAFI levels were suggested to be associated with higher disease stage. With these results, a possible role of elevated TAFI levels in thromboembolic manifestations in the course of multiple myeloma can be suggested.
authors.affiliation: Departments of Hematology, Fatih University Medical School, Turkey.
authors.forename: Ozlem S
authors.initials: OS
authors.lastname: Balcik
authors.forename: Murat
authors.initials: M
authors.lastname: Albayrak
authors.forename: Mehtap E
authors.initials: ME
authors.lastname: Uyar
authors.forename: Simten
authors.initials: S
authors.lastname: Dagdas
authors.forename: Osman
authors.initials: O
authors.lastname: Yokus
authors.forename: Funda
authors.initials: F
authors.lastname: Ceran
authors.forename: Handan
authors.initials: H
authors.lastname: Cipil
authors.forename: Ali
authors.initials: A
authors.lastname: Kosar
authors.forename: Gulsum
authors.initials: G
authors.lastname: Ozet
mesh_terms: D000328:Adult; D025901:Carboxypeptidase B2 / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D005342:Fibrinolysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma; D009367:Neoplasm Staging; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000473:pathology; D012709:Serum Albumin / Q000032:analysis; D054556:Venous Thromboembolism / Q000097:blood* / Q000150:complications / Q000473:pathology; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D006454:Hemoglobins; D012709:Serum Albumin; D001613:beta 2-Microglobulin; D025901:Carboxypeptidase B2